Search results for "Prostate Cancer"

showing 10 items of 413 documents

Innovations thérapeutiques en radiothérapie du cancer de la prostate localisé

2017

Intensity-modulated radiation therapy, image-guided radiation therapy with fiducial markers and prostate brachytherapy allow the delivery of dose escalation for localized prostate cancer with very low rates of long-term toxicity and sequelae. Nowadays, modern radiotherapy techniques make it possible to shorten treatment time with hypofractionation, to better protect surrounding healthy tissues and to escalate the dose even further. Advances in radiotherapy are closely linked to advances in magnetic resonance imaging (MRI) and/or PET imaging. Functional imaging makes it possible to deliver personalised pelvic nodal radiotherapy, targeting the nodal areas at higher risk of microscopic involve…

Index Lesionmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentBrachytherapyMagnetic resonance imagingmedicine.disease3. Good health030218 nuclear medicine & medical imagingRadiation therapy03 medical and health sciencesProstate cancer0302 clinical medicinemedicine.anatomical_structureOncologyProstate030220 oncology & carcinogenesismedicineRadiology Nuclear Medicine and imagingFiducial markerbusinessNuclear medicineProstate brachytherapyCancer/Radiothérapie
researchProduct

ASSOCIAZIONE DI SERENOA REPENS, URTICA DIOICA E PINUS PINASTER. SICUREZZA ED EFFICACIA NEL TRATTAMENTO DEI SINTOMI DEL BASSO TRATTO URINARIO. STUDIO …

2010

INTRODUCTION. Serenoa repens (saw palmetto) has been employed for the treatment of lower urinary tract symptoms (LUTS) for several years. Its mechanism of action is believed to be due to antiandrogenic, antiproliferative and antinflammatory properties. An association of Serenoa with the nettle “Utica dioica” showing antiproliferative activity and the pine “Pinus pinaster” derivative, showing antinflammatory action, has been proposed in recent years. Such an action is hoped to act not only by reducing LUTS but also by preventing the development of prostate cancer. MATHERIAL AND METHODS. During the years 2007 and 2008, 320 patients suffering from LUTS were treated with an association of Seren…

Infiammazione Fitoterapici Iperplasia prostatica Sintomi del basso tratto urinarioCancro della prostataINFLAMMATION Phytotherapy BPH LUTS Prostate cancerSettore MED/24 - Urologia
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct

PRELIMINARY DATA ON PSA CHANGES DURING INTRAVESICAL THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER

2013

Introduction/Aim: Many factors can cause an increase of PSA independently from the presence of prostate cancer . The objective was to evaluate the fluctuation of the serum levels of PSA during adjuvant intravesical chemotherapy or immunotherapy. An increase of PSA due to intravesical BCG and up to 3 months later has been reported (1). Patients and Methods: Patients treated with intravesical chemotherapy or immunotherapy for non- muscle invasive bladder cancer (NMIBC) were entered in the study. Serum samples were collected before starting intravesical therapy, during therapy (within 3rd and 6th instillation) and 30 days after the end of the 6-week induction regimen and during maintenance reg…

Intravesical therapy PSA bladder cancer prostate cancerSettore MED/24 - Urologia
researchProduct

In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellul…

2017

Obesity, metabolic syndrome, and hyperleptinemia are associated with aging and age-associated diseases including prostate cancer. One experimental approach to inhibit tumor growth is to reduce dietary protein intake and hence levels of circulating amino acids. Dietary protein restriction (PR) increases insulin sensitivity and suppresses prostate cancer cell tumor growth in animal models, providing a rationale for clinical trials. We sought to demonstrate that biomarkers derived from plasma extracellular vesicles (EVs) reflect systemic leptin and insulin signaling and respond to dietary interventions. We studied plasma samples from men with prostate cancer awaiting prostatectomy who particip…

LeptinMale0301 basic medicineAgingmedicine.medical_specialtyhyperleptinemiamedicine.medical_treatmentexosomesBiologymetabolic syndrome03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineDiet Protein-RestrictedmedicineHumansInsulinprotein restrictionexosomes; extracellular vesicles; IRS-1; leptin receptor; prostate cancer; protein restriction; Aging; Cell BiologyObesityIRS-1leptin receptorIRS-1; exosomes; extracellular vesicles; leptin receptor; prostate cancer; protein restrictionIRS‐1Caloric RestrictionShort TakesLeptin receptorLeptinInsulinProstatic NeoplasmsShort TakeCell BiologyMiddle Agedprostate cancermedicine.diseaseObesity3. Good healthIRS1Insulin receptor030104 developmental biologyEndocrinologybiology.proteinMetabolic syndromeEnergy Metabolismextracellular vesicles030217 neurology & neurosurgeryage-associated disease
researchProduct

Pilot Study on Predictive Value of Plasmatic Levels of 9 Angiogenetic Biomarkers in Selection of Patients Candidate to Prostate Biopsy

2013

To reduce the number of negative prostate biopsies in patients with elevated PSA serum levels represents a major challenge in urological oncology. Angiogenetic factors might be involved in initial stages of prostate cancer and might represent useful tools in patients’ selection for prostate biopsy. The plasmatic levels of Angiopoietin-2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-BB, PECAM-1 and VEGF were measured by BioPlex immunoassay in patients undergoing prostate biopsy for palpable prostate nodule and/or elevated PSA levels (≥4 ng/mL). They were related with biopsy results. ROC curve analysis was exploited to test the diagnostic accuracy of each biomarker by AUC calculation. A poten…

LeptinMaleOncologymedicine.medical_specialtyPathologyProstate biopsyBiopsyPilot ProjectsAdenocarcinomaUrological oncologyProstate cancerPredictive Value of TestsProstateInternal medicineBiomarkers TumormedicineHumansIn patientAngiogenic ProteinsAgedAged 80 and overProstatic Intraepithelial Neoplasiamedicine.diagnostic_testbusiness.industryPatient SelectionProstateProstatic NeoplasmsGeneral MedicineMiddle AgedProstate-Specific Antigenmedicine.diseaseElevated PSAPredictive valuemedicine.anatomical_structureROC CurveArea Under CurveNeoplasm GradingbusinessUrologia Journal
researchProduct

pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer

2007

During malignant transformation, cancer cells have to evade cell-intrinsic tumor suppressor mechanisms including apoptosis, thus acquiring a phenotype that is relatively resistant to clinically applied anticancer therapies. Molecular characterization of apoptotic signal transduction defects may help to identify prognostic markers and to develop novel therapeutic strategies. To this end we have undertaken functional analyses of drug-induced apoptosis in human non-small cell-lung cancer (NSCLC) cells. We found that primary drug resistance correlated with defects in apoptosome-dependent caspase activation in vitro. While cytochrome c-induced apoptosome formation was maintained, the subsequent …

Lung NeoplasmsTransplantation HeterologousAntineoplastic AgentsApoptosisMice SCIDBiologyMalignant transformationMiceProstate cancerIn vivoCarcinoma Non-Small-Cell LungmedicineAnimalsHumansLung cancerMolecular BiologyIntracellular Signaling Peptides and ProteinsNuclear ProteinsRNA-Binding ProteinsCancerCell Biologymedicine.diseaseCell biologyEnzyme ActivationApoptosisCaspasesCancer cellCancer researchSignal transductionNeoplasm TransplantationCell Death & Differentiation
researchProduct

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prost…

2020

Background TP53 plays critical roles in sensitivity to chemotherapy, and aging. Collagen is very important in aging. The molecular structure and biochemical properties of collagen changes during aging. The discoidin domain receptor (DDR1) is regulated in part by collagen. Elucidating the links between TP53 and DDR1 in chemosensitivity and aging could improve therapies against cancer and aging. Results Restoration of WT-TP53 activity resulted in increased sensitivity to chemotherapeutic drugs and elevated expression of key components of the Raf/MEK/ERK, PI3K/Akt and DDR1 pathways. DDR1 could modulate the levels of Raf/MEK/ERK and PI3K/Akt pathways as well as sensitize the cells to chemothera…

MAPK/ERK pathwayMalecollagenAgingRAF/MEK/ERKMAP Kinase Signaling SystemAntineoplastic Agentsdiscoidin domain receptor (DDR1)DDRCollagen receptorPhosphatidylinositol 3-KinasesDiscoidin Domain Receptor 1Cell Line TumorHumansRapamycinTP53ReceptorProtein kinase BPI3K/AKT/mTOR pathwayDDR1ChemistryWild typeProstateProstatic NeoplasmschemoresistanceCell Biologyprostate cancerDrug Resistance NeoplasmMutationCancer researchraf KinasesTumor Suppressor Protein p53Discoidin domainResearch Paper
researchProduct

Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer…

2021

Background Androgen deprivation therapy (ADT) contributes to lean mass loss and adiposity increases in prostate cancer patients. Radiotherapy during ADT might act synergistically and further worsen body composition. Previous investigations have shown that resistance training is an effective method of preserving body composition during ADT, however, most have not accounted for direct or indirect effects of other therapies, such as radiotherapy. Therefore, the purpose of this study was to examine training adaptations of the tissue composition in patients receiving radiation therapy (RT) prior or during ADT. Methods Analyses were performed by combining data from two previous trials for a total…

Male0301 basic medicineAgingmedicine.medical_treatmentBiochemistryMuscle hypertrophylaw.inventionAndrogen deprivation therapyProstate cancer0302 clinical medicineEndocrinologyRandomized controlled triallawRandomized Controlled Trials as Topicadipositykuntoliikuntamuscle massAndrogensBody Compositionhypertrophyliikuntahoitomedicine.medical_specialtyUrology03 medical and health sciencesAtrophyatrophyGeneticsmedicineHumansAerobic exerciseMuscle StrengthMolecular BiologyatrofiaAgedkehonkoostumussyöpähoidotbusiness.industryProstatic NeoplasmsAndrogen AntagonistsCell Biologymedicine.diseaseRadiation therapysädehoito030104 developmental biologyresistance exerciselihasmassaLean body massbusinesslihassurkastumasairaudet030217 neurology & neurosurgery
researchProduct

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct